-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Alzheimer's disease (AD) is a neurological degenerative disease with hidden development, and its clinical manifestations include memory impairment, aperitosis, defunction, loss of recognition, impairment of visual space skills, and so on.
about 50 million people worldwide suffer from AD.
and tau β are the main pathological characteristics of AD.
Although amyloid β and tau biomarkers in CSF and PET are highly accurate in detecting AD pathology, the cost and low availability required to detect these biomarkers hinder their feasibility in clinical diagnostic practices and clinical trial screening.
suline 181 phosphatized cerebrospinal fluid tau (p-tau181) is a highly specific biomarker of AD pathology.
the purpose of this paper is to assess whether p-tau181 in the blood can be used as a biomarker of Alzheimer's disease and to predict cognitive decline and hema atrophy.
this study developed and validated p-tau181's ultra-sensitive blood immunoanalytical analysis methods to evaluate analytical performance in four clinically based prospective cohorts.
the findings included AD patients and a control group that matched their age.
two validation queues (TRIAD and BioFINDER-2) included participants with normal cognitive abilities (average age 63-69), mild cognitive impairment (MCI), AD, and frontal lobe dementia.
, TRIAD includes healthy young people (average age 23), and BioFINDER-2 includes other neurodegenerative diseases.
The study looked at 37 individuals found in the queue, 226 in the first validation queue (TRIAD), 763 individuals in the second validation queue (BioFINDER-2), and 105 individuals in the primary care queue (n-1131 individuals).
In all the queues, plasma p-tau181 showed a gradual increase along AD, from the lowest concentrations of amyloid β super-negative young adults and cognitively undeficided older adults, to higher concentrations in amyloid β-positive cognitively undetained older persons and mild cognitive impairment groups, to the highest concentrations of amyloid β-positive mild cognitive impairment and Alzheimer's disease groups (p .lt; 0.001).
plasma p-tau181 and PET assayed brain tau (AUC-83.08-93.11%) and amyloid β (AUC-76.14-88.09%) pathology, 1-year cognitive dysfuncation (p-0.0015) and sea horse atrophy (p-0.015).
, the blood p-tau181 test has the potential to be incorporated into clinical practice as a rapid screening trial to exclude pathophysiology from AD and to guide the treatment and clinical management of patients with dementia.
Karikari, Thomas K et al. Blood phosphorylated tau 181 as a biomarker for Alzheimer's disease: a diagnostic performance and prediction modelling study using data from four prospective cohorts. The Lancet Neurology, Volume 19, Issue 5, 422 - 433 MedSci Original Source: MedSci Original Copyright Notice: All text, images and audio and video materials on this website that indicate "Source: Met Medical" or "Source: MedSci Original" are owned by Mets Medical and are not authorized to be reproduced by any media, website or individual.
all reprinted articles on this website are for the purpose of transmitting more information and clearly indicate the source and author, and media or individuals who do not wish to be reproduced may contact us and we will delete them immediately.
at the same time reproduced content does not represent the position of this site.
leave a message here